Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre.

Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre.

OBJECTIVE(S): This study aimed to assess the resource utilisation, health benefits and cost-effectiveness of intra-detrusor injections of botulinum neurotoxin-A (BoNT/A) in patients with overactive bladder (OAB). METHODS: 101 patients with urodynamically-proven detrusor overactivity of either neuro...

Full description

Bibliographic Details
Main Authors:	Kalsi, V, Popat, R, Apostolidis, A, Kavia, R, Odeyemi, I, Dakin, H, Warner, J, Elneil, S, Fowler, C, Dasgupta, P
Format:	Journal article
Language:	English
Published:	2006

Similar Items

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
by: Chiara Traini, et al.
Published: (2019-10-01)

Botulinum Toxin in Neurogenic Detrusor Overactivity
by: Carlos Arturo Levi D'Ancona, et al.
Published: (2012-09-01)

Efficacy of botulinum toxin in a patient with neurogenic detrusor overactivity
by: S. S. Nikitin, et al.
Published: (2022-09-01)

Effect of botulinum toxin type A on idiopathic and neurogenic detrusor overactivity
by: Jurij Leskovar, et al.
Published: (2010-06-01)

Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
by: Cristiano M. Gomes, et al.
Published: (2010-02-01)

Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care.
by: Odeyemi, I, et al.
Published: (2006)

Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients
by: S. Deffontaines-Rufin, et al.
Published: (2011-10-01)

Long term safety outcomes and continuation rates of repeated Intravesical Botulinum Toxin A injections for Detrusor Overactivity: 16 year’s experience of a Tertiary Centre in the UK
by: R. Mohamed-Ahmed, et al.
Published: (2024-03-01)

Concomitant Detrusor and External Urethral Sphincter Botulinum Toxin-A Injections in Male Spinal Cord Injury Patients with Detrusor Overactivity and Detrusor Sphincter Dyssynergia
by: Yu-Hui Huang, et al.
Published: (2022-03-01)

Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice
by: Stephanie Knuepfer, et al.
Published: (2014-02-01)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
by: Shang-Jun Wu, et al.
Published: (2019-01-01)

Investigating Urine Biomarkers in Detrusor Underactivity and Detrusor Overactivity with Detrusor Underactivity Patients
by: Yuan-Hong Jiang, et al.
Published: (2023-04-01)

Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience
by: N K Mohanty, et al.
Published: (2008-01-01)

Intravesical electromotive botulinum toxin-A administration: Will it be the standard treatment for refractory neurogenic detrusor overactivity?
by: Neeraj Kumar Goyal, et al.
Published: (2011-01-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
by: Marcio Augusto Averbeck
Published: (2022-11-01)

OBJECTIVE PARAMETERS TO DESCRIBE DETRUSOR OVERACTIVITY PATTERS
by: T van Steenbergen, et al.
Published: (2023-09-01)

Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury
by: Giuseppe Lombardi, et al.

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
by: Sheng-Fu Chen, et al.
Published: (2021-01-01)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
by: Stacey Tannenbaum, et al.
Published: (2020-12-01)

Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic?
by: Bernard Poulain, et al.
Published: (2019-01-01)

On Botulinum Neurotoxin Variability
by: Cesare Montecucco, et al.
Published: (2015-02-01)

588 ASSOCIATION BETWEEN COMORBIDITY BURDEN AND DETRUSOR OVERACTIVITY WITH DETRUSOR UNDERACTIVITY IN NEUROLOGIC OLDER WOMEN
by: O Ly, et al.
Published: (2022-06-01)

Re: Failure of Botulinum Toxin Injection for Neurogenic Detrusor Overactivity: Switch of Toxin Versus Second Injection of the Same Toxin
by: Lokman İrkilata
Published: (2015-12-01)

Role of detrusor PDGFRα+ cells in mouse model of cyclophosphamide-induced detrusor overactivity
by: Haeyeong Lee, et al.
Published: (2022-03-01)

FREQUENCY OF DETRUSOR LEAK POINT PRESSURES AMONGST PATIENTS WITH URODYNAMIC DIAGNOSIS OF DETRUSOR OVERACTIVITY
by: Nadeem Ahmad, et al.
Published: (2019-08-01)

Novel botulinum neurotoxin-A tibial nerve perineural injection to alleviate overactive bladder symptoms in male rats
by: Seungbeom Kim, et al.
Published: (2022-11-01)

Predicting Refractory Detrusor Overactivity: Are There any Clues at Diagnosis
by: Kylie J Mansfield, et al.
Published: (2013-12-01)

Increased detrusor collagen is associated with detrusor overactivity and decreased bladder compliance in men with benign prostatic obstruction
by: Carlos H.S. Bellucci, et al.
Published: (2017-06-01)

Recent Developments in Botulinum Neurotoxins Detection
by: Christine Rasetti-Escargueil, et al.
Published: (2022-05-01)

Zebrafish Sensitivity to Botulinum Neurotoxins
by: Kamalakar Chatla, et al.
Published: (2016-05-01)

Use of Botulinum Neurotoxin in Ophthalmology
by: Emel Başar, et al.
Published: (2016-12-01)

Antipruritic Effects of Botulinum Neurotoxins
by: Parisa Gazerani
Published: (2018-03-01)

Therapy of Sialorrhea with Botulinum Neurotoxin
by: Wolfgang H. Jost, et al.
Published: (2019-09-01)

Conjugative botulinum neurotoxin-encoding plasmids in Clostridium botulinum.
by: Kristin M Marshall, et al.
Published: (2010-06-01)

Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements
by: Aida Javan Balegh Marand, et al.
Published: (2023-05-01)

Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome.
by: Miguel Silva-Ramos, et al.
Published: (2013-01-01)

Role of percutaneous tibial nerve stimulation in the management of the detrusor overactivity
by: Emad K El Tair, et al.
Published: (2022-01-01)

Coexistent Detrusor Overactivity-Underactivity in Patients with Pelvic Floor Disorders
by: Matteo Frigerio, et al.
Published: (2022-09-01)

Flowmetry/pelvic floor electromyographic findings in patients with detrusor overactivity
by: Farshid Alizadeh, et al.
Published: (2015-06-01)